How Oligonucleotides Work Their Magic
August 20, 2025
Pharma is investing big in oligonucleotides, but what is it that makes this class of drugs so special? We find out.
10 min read
False
Our cover feature highlights the complexities of the fill-finish step – a process that is often underappreciated in pharma manufacturing! Also in this issue, we look at how to align sustainability goals with the complexities of modern supply chains, why oligonucleotides are seeing so much attention in drug discovery, and get the story behind a phase III trial for a new TB vaccine which, if approved, would become the first new TB vaccine in over 100 years. Finally, we interview Cindy Perettie from Kite, a Gilead company.
August 20, 2025
Pharma is investing big in oligonucleotides, but what is it that makes this class of drugs so special? We find out.
10 min read
June 25, 2025
Learning more about the people behind the Power List 2025.
5 min read
June 12, 2025
There has been no new TB vaccine for over 100 years, but a candidate at the Gates Medical Research Institute in phase III has just finished enrolling the target of 20,000 participants.
10 min read
June 2, 2025
Mistakes in fill-finish can lead to lost batches, lost profits, and increased regulatory scrutiny. It’s crucial that this important step gets the attention it deserves. Four experts discuss.
10 min read
April 25, 2025
Depending on the country, only about two in 10 eligible patients, on average, receive CAR T-cell therapy. We sat down with Kite’s Cindy Perettie to talk about access to CAR Ts.
9 min read
May 28, 2024
How pharmaceutical companies are aligning their sustainability goals with the complexities of the modern supply chain
3 min read
False
False
False